ScarX Therapeutics nets $2 mln in Series A financing
Canadian biotechnology company ScarX Therapeutics Inc has obtained $2 million in Series A financing. The investors in the round included Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Innovation. Based in Toronto, ScarX is focused on developing and commercializing dermal scarring treatments that build on the research work of Dr. Benjamin Alman. It plans to use the funds to complete a Phase I clinical trial for its lead candidate, a prescription cream to reduce post-surgical scarring. Founded in 2012, ScarX previously raised $1.7 million in dilutive and $1 million in non-dilutive funding to advance its lead candidate and complete pre-clinical studies.
16 February 2016•3 mins read
